Search Results - "Rodriguez de la Borbolla, Maria"

D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis by Jara-Palomares, Luis, Solier-Lopez, Aurora, Elias-Hernandez, Teresa, Asensio-Cruz, Maria Isabel, Blasco-Esquivias, Isabel, Sanchez-Lopez, Veronica, de la Borbolla, Maria Rodriguez, Arellano-Orden, Elena, Suarez-Valdivia, Lionel, Marin-Romero, Samira, Marin-Barrera, Lucia, Ruiz-Garcia, Aranzazu, Montero-Romero, Emilio, Navarro-Herrero, Silvia, Lopez-Campos, Jose Luis, Serrano-Gotarredona, Maria Pilar, Praena-Fernandez, Juan Manuel, Sanchez-Diaz, Jose Maria, Otero-Candelera, Remedios

“…Background Optimal duration of anticoagulation for cancer-associated thrombosis (CAT) remains unclear. This study assessed D-dimer (DD) and high-sensitivity…”
Get full text

Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study by Jara-Palomares, Luis, Solier-Lopez, Aurora, Elias-Hernandez, Teresa, Asensio-Cruz, Maribel, Blasco-Esquivias, Isabel, Marin-Barrera, Lucia, de la Borbolla-Artacho, Maria Rodriguez, Praena-Fernandez, Juan Manuel, Montero-Romero, Emilio, Navarro-Herrero, Silvia, Serrano-Gotarredona, Maria Pilar, Sánchez-Díaz, José María, Palacios, Carlos, Otero, Remedios

Get full text

Association between sleep-disordered breathing and breast cancer aggressiveness by Campos-Rodriguez, Francisco, Cruz-Medina, Antonio, Selma, Maria Jose, Rodriguez-de-la-Borbolla-Artacho, Maria, Sanchez-Vega, Adrian, Ripoll-Orts, Francisco, Almeida-Gonzalez, Carmen V, Martinez-Garcia, Miguel Angel

“…Sleep-disordered breathing (SDB) has been associated with cancer aggressiveness, but studies focused on specific tumors are lacking. In this pilot study we…”
Get full text

Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study) by Otero, Remedios, Solier-López, Aurora, Sánchez-López, Verónica, Oto, Julia, Arellano, Elena, Marín, Samira, Jara-Palomares, Luis, Elías, Teresa, Asencio, María Isabel, Blasco-Esquivias, Isabel, Rodríguez de la Borbolla, María, Sánchez-Díaz, José María, Real-Domínguez, Macarena, García-Cabrera, Emilio, Rodríguez-Martorell, Francisco Javier, Medina, Pilar

“…The most appropriate duration of anticoagulant treatment for cancer-associated venous thromboembolism (CAT) remains unclear. We have conducted a prospective…”
Get full text

Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma by Trilla-Fuertes, Lucía, Gámez-Pozo, Angelo, Prado-Vázquez, Guillermo, López-Vacas, Rocío, Zapater-Moros, Andrea, López-Camacho, Elena, Lumbreras-Herrera, María I, Soriano, Virtudes, Garicano, Fernando, Lecumberri, Mª José, Rodríguez de la Borbolla, María, Majem, Margarita, Pérez-Ruiz, Elisabeth, González-Cao, María, Oramas, Juana, Magdaleno, Alejandra, Fra, Joaquín, Martín-Carnicero, Alfonso, Corral, Mónica, Puértolas, Teresa, Ramos, Ricardo, Fresno Vara, Juan Ángel, Espinosa, Enrique

“…Immunotherapy based on anti-PD1 antibodies has improved the outcome of advanced melanoma. However, prediction of response to immunotherapy remains an unmet…”
Get full text

Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma by Trilla-Fuertes, Lucía, Gámez-Pozo, Angelo, Prado-Vázquez, Guillermo, López-Vacas, Rocío, Soriano, Virtudes, Garicano, Fernando, Lecumberri, M. José, Rodríguez de la Borbolla, María, Majem, Margarita, Pérez-Ruiz, Elisabeth, González-Cao, María, Oramas, Juana, Magdaleno, Alejandra, Fra, Joaquín, Martín-Carnicero, Alfonso, Corral, Mónica, Puértolas, Teresa, Ramos-Ruiz, Ricardo, Dittmann, Antje, Nanni, Paolo, Fresno Vara, Juan Ángel, Espinosa, Enrique

“…Immunotherapy improves the survival of patients with advanced melanoma, 40% of whom become long-term responders. However, not all patients respond to…”
Get full text

Circulating LncRNAs as predictive biomarkers by molecular subtypes in advanced breast tumors by Salvador, Javier, Pecero, Maria Luisa, Gil, Ana, Rodriguez de la Borbolla, Maria, Ruiz, Manuel, Montano, Alvaro, Gonzalez, Rosario, Benavent Viñuales, Marta, Molina, Sonia

“…Abstract only e23041 Background: Breast cancer is the most common malignant tumor in women worldwide. The leading breast cancer deaths are due to advanced…”
Get full text

Risk factors for complications of Peripherally Catheters Central Insertion (PICC) of prolonged use in patients with solid tumors treated with chemotherapy by Morales Pancorbo, David, Fuentes Pradera, Jose, Jimenez Vilches, Pedro, Escassi, Carmen, Macias Guerrero, Desiree, Fernandez Parra, Eva, Bernabe Caro, Reyes, Lopez Ladron, Amelia, Rodriguez de la Borbolla, Maria, Sanchez, Adrian, Gallego, Inmaculada, Salvador Bofill, Javier

“…Abstract only…”
Get full text

Influence of the localization of the primary tumor in the survival of patients with metastatic colon-rectal cancer treated with bevacizumab by Gallego Jimenez, Inmaculada, Lopez Ladron, Amelia, Morales Pancorbo, David, Fernandez Parra, Eva, Rodriguez de la Borbolla, Maria, Fuentes Pradera, Jose, Bernabe Caro, Reyes, Salvador Bofill, Javier

“…Abstract only 665 Background: Bevacizumab, a humanized antibody against the molecular target endotelial growth factor VEGF-A, has incorporated to the standard…”
Get full text

Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC) by Salvador, Javier, Ruiz Borrego, Manuel, Valero, Maria, Bayo, Juan L., De La Cruz-Merino, Luis, Carabantes, FRancisco, Rodriguez de la Borbolla, Maria

“…Abstract only e11577 Background: The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of…”
Get full text

Prognostic analysis according to the expression of hormone receptors in HER2-positive breast cancer by Gallego Jimenez, Inmaculada, Morales Pancorbo, David, Fuentes Pradera, Jose, Salvador, Javier, Bayo, Juan L., Bernabé, Reyes, Rodriguez de la Borbolla, Maria, Fernandez Parra, Eva, Lopez Ladron, Amelia

“…Abstract only e11075 Background: Overexpression HER 2 + + + is a distinct group within the breast cancer with different treatments in both the adjuvant and…”
Get full text

Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study by Jara-Palomares, Luis, Solier-Lopez, Aurora, Elias-Hernandez, Teresa, Asensio-Cruz, Maribel, Blasco-Esquivias, Isabel, Marin-Barrera, Lucia, de la Borbolla-Artacho, Maria Rodriguez, Praena-Fernandez, Juan Manuel, Montero-Romero, Emilio, Navarro-Herrero, Silvia, Serrano-Gotarredona, Maria Pilar, Sánchez-Díaz, José María, Palacios, Carlos, Otero, Remedios

“…The safety and efficacy of low-molecular-weight heparin (LMWH) treatment in patients with cancer-associated thrombosis (CAT) beyond 6months are unknown. Our…”
Get full text

Effectiveness and safety of eribulin for human epidermal growth factor receptor 2 negative metastatic breast cancer in a real-world population by Díaz-Acedo, Rocío, Artacho Criado, Silvia, Jiménez Galán, Rocío, Gutiérrez Pizarraya, Antonio, Galván Banqueri, Mercedes, Rodríguez-de-la-Borbolla-Artacho, María, Marcos Rodríguez, José Antonio, Márquez Saavedra, Esther

“…Background Eribulin’s clinical benefit remains unclear; so, studies analyzing its effectiveness in routine clinical practice are interesting. Patients and…”
Get full text

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study by Martín Algarra, Salvador, Soriano, Virtudes, Fernández-Morales, Luis, Berciano-Guerrero, Miguel-Ángel, Mujika, Karmele, Manzano, José Luis, Puértolas Hernández, Teresa, Soria, Ainara, Rodríguez-Abreu, Delvys, Espinosa Arranz, Enrique, Medina Martínez, Javier, Márquez-Rodas, Ivan, Rubió-Casadevall, Jordi, Ortega, María Eugenia, Jurado García, José Miguel, Lecumberri Biurrun, María José, Palacio, Isabel, Rodríguez de la Borbolla Artacho, María, Altozano, Javier Pérez, Castellón Rubio, Victoria Eugenia, García, Almudena, Luna, Pablo, Ballesteros, Anabel, Fernández, Ovidio, López Martín, Jose Antonio, Berrocal, Alfonso, Arance, Ana

“…The main objective of the study was to evaluate the efficacy and safety of dabrafenib alone or combined with trametinib for compassionate use in patients with…”
Get full text

Unveiling the relationship between the UGT2B gene family and neoadjuvant treatment response in patients with HER2-positive breast cancer by Gil, Ana, Dominguez-Cejudo, M Ángeles, Molina-Pinelo, Sonia, Pascual, Javier, Rodríguez-Alonso, Beatriz, Rodríguez de la Borbolla, María, Benavent Viñuales, Marta, Cejuela Solís, Mónica, Falcon, Alejandro, Miras, Isabel, Ruiz-Borrego, Manuel, Amerigo Góngora, Marta, Bofill, Javier Salvador

“…e12651 Background: Achieving a pathological complete response (pCR) following neoadjuvant treatment (NAT) in HER2-positive tumors significantly enhances…”
Get full text

Analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with carboplatin-paclitaxel after multiple lines of treatment by Fernández Pérez, Elisa María, Beltrán Guerra, Isabel, Sánchez Vegas, Adrian, Robles, Carlos Enrique, Lourenzo Aguilera, Gloria, Fernández Carcaño, Marta, Ayala De Miguel, Carlos, Díaz López, Sebastián, García González, Guillermo, Bachurin, Leonid, Rico López, Javier, Fuentes Pradera, Jose, Jimenez Castro, Jeronimo, Rodríguez de la Borbolla, María, López Álvarez, Pilar, Gómez Reina, María José, Chaves Conde, Manuel, Fernández Parra, Eva

“…144 Background: Metastatic castration-resistant prostate cancer (mCRPC) occurs in men with advanced disease progressing to androgen deprivation therapy, with…”
Get full text

Effectiveness and safety of neoadjuvant therapy in triple-negative breast cancer in a real-world population by Galindo García, Cristina, Díaz Acedo, Rocío, Artacho Criado, Silvia, Rodríguez de la Borbolla Artacho, María

“…Triple-negative breast cancer is a subtype of aggressive breast cancer. Our aim is to evaluate the effectiveness and safety of neoadjuvant treatment in…”
Get full text

[Artículo traducido] Efectividad y seguridad del tratamiento neoadyuvante del cáncer de mama triple negativo en la vida real by Galindo García, Cristina, Díaz Acedo, Rocío, Artacho Criado, Silvia, Rodríguez de la Borbolla Artacho, María

“…el cáncer de mama triple negativo es un subtipo agresivo de cáncer de mama. Nuestro objetivo es evaluar la eficacia y seguridad del tratamiento neoadyuvante en…”
Get full text